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Abstract
The author reports a very rare and very unique urinary bladder carcinoma. This carcinoma
occurred in a 68-year-old Japanese patient who underwent cystectomy for bladder tumor. The
tumor was large polypoid and ulcerated one. Histologically, the tumor consisted of the following
three elements: giant cell sarcomatoid carcinoma (70% in area), squamous cell carcinoma (20% in
area), and papillary urothelial transitional cell carcinoma (10% in area). The former two elements
were invasive into the peribladder fat tissue, while the latter one element invaded into the
submucosa. There were gradual merges between the giant cell sarcomatoid element and squamous
cell carcinoma element. Apparent transitions were not seen between the transitional cell
carcinoma element and the giant cell sarcomatoid element or the squamous cell carcinoma
element. Immunohistochemically, the giant cell sarcomatoid element was positive for various kinds
of cytokeratins and vimentin while the squamous and transitional cell carcinoma elements were
positive for various kinds of cytokeratins and negative for vimentin. The giant cell sarcomatoid
element was free of other specific antigens. The author speculates that giant cell sarcomatoid
carcinoma transdifferentiates into squamous cell carcinoma, and vice versa. The relationship
between transitional cell carcinoma and the other two elements is unclear in the present case.
Introduction
Sarcomatoid carcinoma is a well known entity of the uri-
nary bladder [1-8]. Squamous cell carcinoma of the uri-
nary is well known to occur in the urinary bladder [9]. In
most of these cases, foci of urothelial carcinoma are
present within such tumors. However, sarcomatoid carci-
nomas of the urinary bladder with compoments of squa-
mous cell carcinoma and urothelial transitional cell
carcinoma have not been reported, to the best of the
author's knowledge. Here, the author reports a unique
and very rare case of giant cell sarcomatoid carcinoma
with squamous cell carcinoma component and papillary
urothelial transitional cell carcinoma component.
Case presentation
A 68-year-old Japanese man was admitted to our hospital
because of sudden hematuria and abdominal pain. Endo-
scopic and imaging techniques including CT, MRI, and
PET revealed a bladder tumor. Transurethral biopsy and
clinical cytology revealed malignant tumor composed of
giant cells, and cystectomy was performed. Macroscopi-
cally, the bladder contained a large polypoid and ulcer-
ated reddish tan tumor (5 × 6 cm).
For histological evaluation, 17 tissue specimens were
obtained from the tumor. Histologically, the tumor con-
sisted of the following three elements: giant cell sarcoma-
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toid carcinoma (70% in area), squamous cell carcinoma
(20% in area), and papillary urothelial transitional cell
carcinoma (10% in area) (Figure 1). The giant cell sarco-
matous element and squamous cell carcinoma element
were invasive into the peribladder fat tissue, while the
transitional cell carcinoma element was invasive into the
submucosa.
The sarcomatoid element was composed of malignant
polygonal and spindle giant cells with frequent multinu-
cleated giant cells (Figure 2). The giant cells had hyper-
chromatic nuclei and showed many mitotic figures. The
giant cell sarcomatoid carcinoma area was homologous,
and did not show heterologous elements such as bones
and cartilages. Specific structures including herring bone
and storiform appearances were not recognized. The
tumor cells did not show plasmacytoid features. Lym-
phocytic infiltration was absent.
The squamous cell carcinoma element was composed of
malignant squamous cell with individual keratinization
and intercellular bridge formation. Many mitotic figures
were recognized in the squamous cell carcinoma element.
There were gradual merges between the giant cell sarco-
matoid and squamous cell carcinoma elements (Figure 3).
There were occasional lymphovascular permeations by
the giant cell sarcomatoid carcinoma and squamous cell
carcinoma elements.
The papillary urothelial transitional cell carcinoma was
grade II carcinoma with a few lymphovascular permea-
tions. No transitions were observed between the transi-
tional cell carcinoma element and the other two elements.
An immunohistochemical study was performed with the
use of Dako Envision method, as previously reported
[10,11]. The reagents and results are shown in Table 1.
The giant cell sarcomatoid carcinoma element was posi-
tive for various kinds of cytokeratins, epithelial mem-
brane antigen, and vimentin. It was negative for other
mesenchymal markers such as desmin and S100 protein.
P53 protein was positive and Ki-67 labeling was 72%. It
was negative for CD68. The squamous cell carcinoma ele-
The bladder tumor Figure 1
The bladder tumor. The tumor consists of squamous cell 
carcinoma (center) and giant cell sarcomatoid carcinoma. HE, 
×40.
High power view of sarcomatoid carcinoma Figure 2
High power view of sarcomatoid carcinoma. It is com-
posed of giant cells of spindle and polygonal shapes. The ple-
omorphism is very high. Many malignant multinucleated giant 
cells are also recognized. HE, ×200.
High power view of a small focus of squamous cell carcinoma Figure 3
High power view of a small focus of squamous cell 
carcinoma. Transitions between squamous cell carcinoma 
and giant cell sarcomatoid carcinoma are recognized. HE, 
×200.Cases Journal 2009, 2:9111 http://www.casesjournal.com/content/2/1/9111
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ment was strongly positive for various types of cytokerat-
ins and epithelial membrane, but was negative for
vimentin and other mesenchymal markers. Neuroendo-
crine antigens and melanoma antigens were absent. P53
was positive, and Ki-67 labeling was 72%. The papillary
urothelial transitional cell carcinoma element showed the
similar results to those of the squamous cell carcinoma
element, but the former was positive for cytokeratin 20
(Table 1). Both the epithelial elements were positive for
p53 and showed high Ki67 labeling (squamous cell carci-
Table 1: Reagents and results in immunohistochemistry.
Antigens Antibodies (clone) Sources Giant cell sarcomatoid SCC TCC
Pancytokeratin AE1/3 Dako Corp. Glostrup, Denmark ++ +++ +++
Pancytokeratin CAM5.2 Becton Dickinson Co. CA, USA ++ +++ +++
HMWCK 34βE12 Dako + + ++
CK5/6 D5/16 Dako + ++ ++
CK7 N1626 Dako + + ++
CK8 35βH11 Dako + ++ ++
CK14 LL002 Novocastra, Newcastle upon type, UK + + ++
CK 18 DC10 Dako ++ +++ +++
CK 19 RCK 108 Progen, Heidelberg, Germany - + +
CK20 K20.8 Dako - - ++
EMA E29 Dako + + ++
Chromogranin DAK-A3 Dako - - -
Synaptophysin Polyconal Dako - - -
CD56 MOC-1 Dako - - -
CD68 KP-1 Dako - - -
Melanosome HMB45 Dako - - -
Vimentin Vim 3B4 Dako +++ - -
Desmin D33 Dako - - -
S100 protein polyclonal Dako - - -
ASMA 1A4 Dako - - -
Myoglobin polyclonal Dako - - -
CD34 NU-4A1 Nichirei, Tokyo, Japn - - -
p53 protein DO-7 Dako ++ ++ +
Ki-67 MIB-I Dako 72% 67% 32%
SCC, squamous cell carcinoma; TCC, transitional cell carcinoma area; +++, 67-100% positive; ++, 33-66%; +, 1-33% positive; -, negative; HMWCK, 
high molecular weight cytokerain; CK, cytokeratin; EMA, epithelial membrane antigen; ASMA, α-smooth muscle antigen.Cases Journal 2009, 2:9111 http://www.casesjournal.com/content/2/1/9111
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noma, 67%; transitional cell carcinoma, 32%). Other
antigens examined were negative (Table 1).
A diagnosis of bladder carcinoma composed of three dif-
ferent elements was made. The patient was treated by pal-
liative chemotherapy and radiation, but died of systemic
metastases 32 months after the operation. Autopsy was
not performed.
Discussion
In the present case, the percentage of areas of each ele-
ment was as follows: giant cell sarcomatoid carcinoma
(70% in area), and squamous cell carcinoma (20% in
area), and papillary transitional cell carcinoma (10% in
area). The sarcomatoid element predominated over other
elements. Therefore, the present cases can be labeled as
giant cell sarcomatoid carcinoma.
The present case is not carcinocarcoma or sarcoma,
because the sarcomatoid giant tumor cells were positive
for cytokeratins and vimentin and negative for other mes-
enchymal antigens. The giant cell sarcomatoid compo-
nent of the present case is different from "sarcomatous
stroma", which is a bladder sarcomatoid reaction like
nodular fasciitis of the skin [12,13]. It often occurs after
bladder mucosal injuries. It is characterized by edema and
inflammatory infiltration, and is usually negative for
cytokeratins and positive for smooth muscle actin or
vimentin [12,13]. The present case lacked such features of
"sarcomatoid stroma" of the urinary bladder. The giant
cells of the present giant cell sarcomatoid carcinoma are
different from osteoclast-like giant cells rarely seen in sar-
comatoid carcinoma [7,14], because the giant cells were
positive for cytokeratins and negative for CD68 and also
because the histologies of giant cells were entirely differ-
ent from the osteoclast-like giant cells. The present sarco-
matoid carcinoma is not rarely-reported giant cell tumor
[15], because of different morphologies and because the
present tumor expressed cytokeratins. The giant cell sarco-
matoid carcinoma area in the present case showed homol-
ogous histology, and features of storiform-pleomorphic,
herring bone, formations of bones and cartilages, plasma-
cytoid, and lymphoepithelial carcinoma are absent. The
area was negative for neuroendocrine antigens, so that the
area is not large cell neuroendocrine carcinoma. The
present tumor is not malignant melanoma.
The pathogenesis of sarcomatoid carcinoma of the urinary
bladder is only speculative despite of many studies [1-8].
Almost all cases of sarcomatoid carcinoma of the bladder
contain foci of urothelial transitional cells carcinoma [1-
8]. Previous studies have suggested that the sarcomatous
component of sarcomatoid bladder carcinoma is derived
from urothelial carcinoma. Interestingly, Sung et al. [8]
have recently suggested the monoclonal nature of sarco-
matoid bladder carcinoma with the use of molecular tech-
niques. This finding strengthens the concept that the
bladder sarcomatoid carcinoma is monoclonal lesion
derived from urothelial carcinoma.
In the present study, there were close associations
between giant cell sarcomatoid carcinoma element and
squamous cell carcinoma element. There were frequent
histological merges between the two elements. This may
indicate that the squamous cell carcinoma element in the
present case was derived from trans-differentiation from
the giant cell sarcomatoid carcinoma element, or that the
giant cell sarcomatoid carcinoma element was derived
from the squamous cell carcinoma element. The present
study strongly suggested the monoclonal natures of the
sarcomatoid carcinoma and squamous cell carcinoma in
bladder sarcomatoid carcinomas. Much more studies
using molecular genetic analyses such as LOH analyses are
required in sarcomatoid carcinomas of the bladder.
The present study did not show spatial relationship
between urothelial papillary transitional cell carcinoma
and the other two elements. Previous studies have sug-
gested that the sarcomatoid area of the bladder sarcoma-
toid carcinoma is derived from urothelial transitional
carcinoma [1-8]. It is possible that in the present study,
sarcomatoid carcinoma and squamous cell carcinoma ele-
ments are not associated with urothelial transitional cell
carcinoma element. However, this is not always true.
Much more studies using a large series and molecular
analyses of bladder sarcomatoid carcinoma is mandatory
to determine the pathogenesis of this rare tumor.
Finally, sarcomatoid carcinoma of the urinary bladder
tends to be high grade and shows a poor prognosis than
usual urothelial carcinoma [1-8]. In the present case, the
survival period was 32 months after the operation. A crit-
ical studies on the mechanism(s) of the development of
sarcomatoid carcinoma of the urinary bladder are needed
to obtain the radical therapy for this rare neoplasm.
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